secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2026-08-13T11:00:34+00:00
Accession:  0001919246-26-000110
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos Therapeutics restates Q1 2026 results due to convertible debt valuation error
--------------------------------------------------------------------------------

- Non-reliance on Q1 2026 10-Q; restatement due to ASC 820 misapplication for Level 3 convertible debt fair value.
- Restatement increases convertible debt fair value by $15.8M, accumulated deficit by $14.8M, reduces AOCI by $1.0M.
- Non-cash expense up $14.8M; no impact on revenue, operating expenses, or cash position.
- Material weakness in internal controls over Level 3 fair value measurements; remediation planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000110/0001919246-26-000110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000110/pths-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001919246-26-000110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer